Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arman Taghizadeh

Psychiatry Baltimore, MD Medical Doctor

NPI 1760528301 CMS profile 954399

600 N Wolfe St, Baltimore, MD 21287

Open in the dashboard

General payments

$5,473

261 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arman Taghizadeh of Baltimore, MD is reported in the CMS Open Payments database as having received $5,473 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $343 12
2024 General $516 28
2023 General $310 15
2022 General $565 26
2021 General $1,223 57
2020 General $1,090 58
2019 General $1,426 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arman Taghizadeh
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Arman Taghizadeh were reported at $343. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Arman Taghizadeh Psychiatry median Middle half National median
2019 $1,426 $184 $59–$605 $163
2020 $1,090 $119 $36–$372 $114
2021 $1,223 $143 $43–$576 $132
2022 $565 $153 $50–$590 $149
2023 $310 $170 $56–$651 $160
2024 $516 $179 $57–$673 $164
2025 $343 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neos Therapeutics, LP $2,580 121 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,201 50 payments
  3. Tris Pharma Inc $453 25 payments
  4. Allergan Inc. $236 19 payments
  5. Vertical Pharmaceuticals, LLC $146 9 payments
  6. Alkermes, Inc. $128 1 payment
  7. AbbVie, Inc. $101 4 payments
  8. Bausch Health US, LLC $100 4 payments
  9. Shire North American Group Inc $89 5 payments
  10. Supernus Pharmaceuticals, Inc. $75 4 payments
  11. Other $364 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,473 261 payments
Products named General payments · program years 2019–2025
  1. COTEMPLA XR-ODT $2,050 95 payments
  2. Adzenys XR-ODT Adhd $933 39 payments
  3. TRINTELLIX Neuroscience $853 35 payments
  4. Adzenys XR-ODT Adhd $594 29 payments
  5. Quillivant XR $320 18 payments
  6. VRAYLAR $236 19 payments
  7. Trintellix Central Nervous System (CNS) $223 10 payments
  8. VYVANSE $213 10 payments
  9. Relexxii $146 9 payments
  10. LYBALVI $128 1 payment
  11. Other $1,451 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

107

Median for Psychiatry & Neurology: 100

Drug cost

$6,150

Median for Psychiatry & Neurology: $2,986

Branded share of claims

37.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyvanse Lisdexamfetamine Dimesylate Brand 12 $4,202
Vilazodone Hcl Generic 17 $1,184
Guanfacine Hcl Er Guanfacine Hcl Brand 12 $360
Bupropion Xl Bupropion Hcl Brand 16 $284
Sertraline Hcl Generic 26 $45
Clonazepam Generic 12 $45
Trazodone Hcl Generic 12 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COTEMPLA XR-ODT
  • Neos Therapeutics, LP $213
$213 — —
Relexxii
  • Vertical Pharmaceuticals, LLC $114
$114 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $82
$82 — —
VRAYLAR
  • AbbVie, Inc. $78
$78 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record